

trans-Golgi Retention of a Plasma Membrane Protein: Mutations in the Cytoplasmic Domain of the Asialoglycoprotein Receptor Subunit H1 Result in *trans*-Golgi Retention

Johanna M. Wahlberg, Iris Geffen, Françoise Reymond, Thomas Simmen, and Martin Spiess

Department of Biochemistry, Biozentrum, University of Basel, CH-4056 Basel, Switzerland

Abstract. Unlike the wild-type asialoglycoprotein receptor subunit H1 which is transported to the cell surface, endocytosed and recycled, a mutant lacking residues 4-33 of the 40-amino acid cytoplasmic domain was found to be retained intracellularly upon expression in different cell lines. The mutant protein accumulated in the *trans*-Golgi, as judged from the acquisition of *trans*-Golgi-specific modifications of the protein and from the immunofluorescence staining pattern. It was localized to juxtannuclear, tubular structures that were also stained by antibodies against galactosyltransferase and γ -adaptin. The results of further mutagenesis in the cytoplasmic domain indicated that the size rather than the specific sequence of the cytoplasmic domain deter-

mines whether H1 is retained in the *trans*-Golgi or transported to the cell surface. Truncation to less than 17 residues resulted in retention, and extension of a truncated tail by an unrelated sequence restored surface transport. The transmembrane segment of H1 was not sufficient for retention of a reporter molecule and it could be replaced by an artificial apolar sequence without affecting Golgi localization. The cytoplasmic domain thus appears to inhibit interaction(s) of the exoplasmic portion of H1 with *trans*-Golgi component(s) for example by steric hindrance or by changing the positioning of the protein in the membrane. This mechanism may also be functional in other proteins.

TRANSPORT of proteins through the secretory pathway appears to occur by default (Pfeffer and Rothman, 1987). In contrast, localization to individual compartments (by retention or retrieval) requires specific signals (Pelham and Munro, 1993), such as the carboxy-terminal sequence KDEL and the cytoplasmic motif K(X)KXX for retrieval to the ER of luminal and membrane proteins, respectively. The determinants for retention in Golgi compartments have so far been shown to comprise the transmembrane domain with or without flanking sequences. Proteins leaving the Golgi apparatus are sorted in the *trans*-Golgi network (TGN) largely by signal-dependent mechanisms into specific transport vesicles to secretory granules, apical or basolateral plasma membrane, or endosomes.

In the endoplasmic reticulum (ER), in addition, there are mechanisms to prevent improperly folded or oligomerized proteins from exiting and to degrade them. The ER thus performs a quality control function for secretory and membrane proteins (Hurtley and Helenius, 1989). Many natural and artificial mutations in such proteins have been observed to result in ER retention and degradation, apparently because they affect protein folding or oligomerization. Alterations in the signals for targeted exit from the TGN generally cause missorting rather than TGN localization of the mutant. Only very few mutations have been

documented that cause a specific accumulation of the mutant protein in post-ER compartments of the secretory pathway. Such mutations may reflect properties of retention or transport mechanisms in the Golgi. Here we describe mutants of the asialoglycoprotein (ASGP)¹ receptor subunit H1 that specifically accumulate in the *trans*-Golgi.

The ASGP receptor is an endocytic transport receptor responsible for the rapid clearance of glycoproteins with exposed galactoses from the circulation into hepatocytes (for review see Spiess, 1990). Ligand ASGPs are bound at the cell surface, internalized via clathrin-coated vesicles, and released in the acidic environment of endosomes for subsequent degradation in lysosomes. The ASGP receptor cycles constitutively between the cell surface and early endosomes. The human receptor is at least a trimer composed of two homologous subunits, H1 and H2, which both are required for high affinity ligand binding. The subunits are single-spanning type II membrane proteins with amino-terminal cytoplasmic domains of 40 and 58 residues, respectively. The major subunit H1, which is 2-4 times more abundant than H2, contains all the signals necessary for endocytosis and specific basolateral transport in

1. *Abbreviations used in this paper:* ASGP, asialoglycoprotein; M6P, manose-6-phosphate.

polarized epithelial cells (Geffen et al., 1989; Wessels et al., 1989). A tyrosine-containing signal necessary for efficient endocytosis and basolateral sorting has been identified in the amino-terminal segment of residues 1-11 (Fuhrer et al., 1991; Geffen et al., 1993). Mutation of the critical tyrosine at position 5 to alanine or deletion of residues 4-11 result in apolar sorting in transfected MDCK cells and in accumulation of H1 at the plasma membrane in transfected fibroblast and MDCK cells.

As part of these studies, an H1 mutant lacking most of the cytoplasmic domain (residues 4-33) was constructed (Geffen et al., 1993). Although this mutant protein exits the ER, it is not detectable at the cell surface. Here we show that it accumulates specifically in a *trans*-Golgi compartment. The sequence requirement for retention or exit to the plasma membrane was investigated by further mutagenesis. The results indicate that the size of the cytoplasmic domain determines the fate of the protein and modulates an intrinsic ability of the transmembrane and/or exoplasmic portion of H1 to interact with component(s) resident in the *trans*-Golgi. Such a mechanism may be functional also for other *trans*-Golgi/plasma membrane proteins.

Materials and Methods

Construction of Mutant Proteins

Mutagenesis of the cDNAs encoding the mutants H1(Δ 4-33A), H1(Δ 4-11), and H1(Δ 12-33) have been described previously (Beltzer et al., 1991; Geffen et al., 1993). H1(Δ 12-33/5A) was constructed using the mutagenesis kit by Amersham Corp. (Arlington Heights, IL), the cDNA of H1(Δ 12-33) subcloned into M13mp19 as the template, and the anti-sense oligonucleotide GGTCTTGAQCCTCCTG as the primer (the mismatched nucleotides are underlined). To generate the cDNA of H1(Δ 4-33m), two complementary oligonucleotides were synthesized, CCAGGAACAAAAGTTGATTTCTGAAGAAGACTTGGCTGCA and GCCAAGTCTTCTCAGAAATCAACTTTTGTTTC, which encode the *c-myc* epitope EQKLISEEDLA recognized by the monoclonal antibody 9E10 (Evan et al., 1985) and produce "sticky ends" for in-frame insertion between the StyI site at codons 2/3 and the PstI site at codons 32/33 of the H1 cDNA.

The other cDNA constructs were made by polymerase chain reaction (PCR) using the wild-type cDNA of H1 (Spiess et al., 1985; Hind III-EcoRI subcloned into pSP64 or pGEM3) as the template, a mutagenic primer and a second primer corresponding to a flanking sequence in the plasmid vector. For H1(Δ Pro), a 5' cDNA fragment containing codons 1-24 and 31-33 was amplified using the oligonucleotide CGTCTGCAGAGCCCTTTTCTGAGCTG as the mutagenic primer. Codons 32 and 33 correspond to a PstI restriction site that was used to ligate this amplified 5' segment to the 3' rest of the H1 cDNA starting from this PstI site. The H1(Δ 2-37) construct was made using the mutagenic primer CCTAC-CATGGGACCTCGCCTCCT to amplify an amino terminally truncated cDNA with an ATG and an NdeI restriction site for subcloning. The cDNAs of H1(Δ 2-19), H1(Δ 2-24), H1(Δ 2-28), H1(Δ 2-33), and H1(Δ 26-40) were constructed by PCR and splicing by overlap extension according to Ho et al. (1989a), thereby retaining the original 5' untranslated sequence and ATG.

To construct H1T, the cDNA corresponding to the cytoplasmic domain of the mouse transferrin receptor (from L. Kühn, ISREC) was amplified by PCR from the plasmid pMTR-1 using the mutagenic primer TCC-CCAGTTCGACCATTAAAC, which introduces a SalI site (underlined) at the end, and a primer corresponding to a flanking sequence in the plasmid vector. The cDNA corresponding to the transmembrane and exoplasmic domains of H1 were amplified similarly with the primer CCGGAC-GTCGACTCCTCCTG, which introduces a SalI site at the beginning of the transmembrane domain. The PCR products were subcloned and ligated to each other at the SalI site. The cDNA of H1TA was constructed by PCR from the plasmid encoding H1T using the mutagenic primer GGGGTACCATGGTTCAGAAAACCCAAGAGG to amplify a truncated cDNA with a 5' ATG and a KpnI restriction site for subcloning.

To construct the cDNA of AN2 and AN2 Δ a BamHI site was introduced into the aminopeptidase N cDNA at codons 33/34 corresponding to the exoplasmic end of the transmembrane domain using the mutagenic anti-sense primer TCCTGGGATCCCACCACTG and the Amersham mutagenesis kit. The cDNA fragment 3' of this BamHI site was ligated to the 5' HindIII-BamHI fragment of either H1 or H1(Δ 4-33A) cDNA. From the plasmid 19L, a gift from G. von Heijne (Karolinska Institute, Huddinge, Sweden) a sequence encoding 19 leucines, preceded by a KpnI site and the codons for Met-Gly-Pro-Arg, and followed by a BamHI site was amplified by PCR and ligated in front of the BamHI-EcoRI fragment of H1 cDNA to obtain the construct for H1 Δ Leu₁₉. The construct for H1Leu₁₉ was made by ligating the HindIII-NruI fragment of plasmid pSA11/3 (Spiess and Handschin, 1987) to the H1 Δ Leu₁₉ cDNA cut with KpnI and blunted.

To generate the cDNA of H1(Δ 4-33A)^{TS}, a variant of H1(Δ 4-33A) tagged with a tyrosine-sulfation peptide at the carboxy terminus, the 3' portion (BamHI-EcoRI) of the cDNA of H1(Δ 4-33A) was replaced by that of H1^{TS} described by Leitinger et al. (1994). To construct H1(Δ 4-33A)^{myc}, a variant containing a carboxy-terminal *c-myc* epitope tag, the tyrosine-sulfation tag sequence (KpnI-SacI) of the H1^{TS} cDNA was replaced by two complementary oligonucleotides, CGAACAAAAGTTGATTTCTGAAGAAGACTTGAAGCTGAGCT and CAGTTCAGAAATCTTCTCAGAAATCAACTTTTGTTTCGGTAC, which encode the peptide sequence EQKLISEEDLN followed by a stop codon and produce terminal protruding ends corresponding to a KpnI and a SacI site at the 5' and 3' end, respectively. All mutagenized segments were confirmed by DNA sequencing.

Cell Culture and Transfection

MDCK (strain II), COS-7, HepG2, and HeLa cells were grown in minimal essential medium (MEM) with 10% FCS, NIH 3T3 cells in Dulbecco's modified MEM with 10% newborn calf serum, CaCo-2 cells in DMEM with 20% FCS and 1% nonessential amino acids (GIBCO BRL, Gaithersburg, MD), and BHK-21 cells in Glasgow MEM with 5% FCS and 10% tryptose phosphate broth (Gibco). All culture media were supplemented with 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin.

For transient expression, cDNA constructs were subcloned into the SV40-based expression vector pECE (Ellis et al., 1986) and transfected using DEAE-dextran as described by Cullen (1987). The next day transfected cells were trypsinized and seeded onto coverslips and processed for immunofluorescence microscopy 36-40 h after transfection.

Preparation of the stable MDCK cell lines M1, M1 Δ (= M1[Δ 4-33A]), M1^{TS}, M2, M12 (= M[Y+f]) has been described previously (Wessels et al., 1989; Geffen et al., 1993; Leitinger et al., 1994; Fuhrer et al., 1994). To produce stable cell lines, the cDNA of H1(Δ 4-33A)^{TS} was cloned into pK21 (with a cytomegalovirus promoter; provided by R. Gentz, Hoffmann-La Roche, Basel), and transfected into MDCK cells together with one tenth the amount of the resistance plasmid pSVneo using polybrene and dimethyl sulfoxide according to Kawai and Nishizawa (1984). Clonal cell lines resistant to 0.5 mg/ml G418-sulfate were isolated and screened for expression by immunofluorescence and immunoblot analysis using a polyclonal antiserum directed against the ASGP receptor. The cDNA of H1(Δ 4-33A) was subcloned into pBamHis (with a murine leukemia virus promoter and the *Salmonella his* gene as a resistance marker; from R. Mulligan, Whitehead Institute, Cambridge, MA) and transfected into the cell line M2, an MDCK-derived cell line expressing the second ASGP receptor subunit H2 and G418 resistance (Fuhrer et al., 1994). Clonal cell lines were selected in the presence of 2 mg/ml histidinol. The resulting cell lines were named M1 Δ ^{TS} and M2/1 Δ , respectively.

Biochemical Analyses

The surface/intracellular distribution of H1 variants was assayed by treating intact cells with 1 mg/ml proteinase K in PBS containing 5 mM EDTA for 30 min at 4°C or 37°C. Digestion was stopped by adding 2 mM PMSF. Digested and control cells were lysed in gel sample buffer and subjected to SDS-gel electrophoresis and immunoblot analysis using ¹²⁵I-iodinated protein A. Autoradiographs were quantitated by densitometric scanning. The high mannose precursor form was used as an internal standard in calculating the fraction of resistant mature form.

For carbohydrate analysis, cells were solubilized in lysis buffer (1% Triton X-100, 0.5% deoxycholate, 2 mM PMSF in PBS) and incubated with 2 mU endo- β -N-acetylglucosaminidase H or 5 mU neuraminidase (Boehringer Mannheim Corp., Indianapolis, IN) for 3 h at 37°C in 100 μ l. Samples were analyzed by SDS-gel electrophoresis and immunoblotting.




Figure 2. Immunofluorescence localization of wild-type H1 and H1(Δ 4-33A). Cells expressing H1 or H1(Δ 4-33A) were processed for indirect immunofluorescence microscopy with (*B*, *D*, *E*, and *F*) or without (*A* and *C*) permeabilization and stained using anti-ASGP receptor antiserum. (*A* and *B*) M1 cells, a stable MDCK cell line expressing wild-type H1. (*C* and *D*) M1 Δ cells, a stable MDCK cell line expressing H1(Δ 4-33A). (*E*) Stable NIH/3T3 cells expressing H1(Δ 4-33A). (*F*) BHK-21 cells transiently transfected with H1(Δ 4-33A) cDNA. Bar, 5 μ m.

ing pattern could be observed for H1(Δ 4-33A) expressed by a stable NIH/3T3 fibroblast cell line (*E*) and by transiently transfected BHK-21 (*F*), COS-7, CaCo-2, and HeLa cells (not shown). In 5–10% of the transiently transfected cells, but not in the stable cell lines, the mutant protein could be detected also on the cell surface in addition to the typical intracellular structures. Since surface appearance of H1(Δ 4-33A) was also observed in a small fraction of mock-transfected M1 Δ cells, this phenomenon is probably caused by the transfection conditions.

The absence of H1(Δ 4-33A) from the cell surface was

confirmed biochemically by immunoblot analysis of proteinase K digested M1 Δ and M1 cells (Fig. 3). In untreated cells, two immunoreactive forms of 40 kD and 45 kD for H1, and 35 kD and 40 kD for H1(Δ 4-33A) were detected. The two forms of each protein correspond to the high-mannose glycosylated precursor which is sensitive to endoglycosidase H (endo H) digestion and to the complex glycosylated, endo H-resistant form (Fig. 4, lanes 1–5). Upon proteinase K digestion at 4°C, 50% of the mature form of H1 was degraded in M1 cells (normalized to the precursor form; Fig. 3, lanes 4 and 5). This corresponded




Figure 3. Surface expression of H1 and H1(Δ 4-33A). Intact HepG2, M1, and M1 Δ cells were incubated at 4°C or 37°C for 30 min with (PK) or without (-) proteinase K as indicated. After blocking the protease, the cells were solubilized and subjected to gel electrophoresis and immunoblot analysis using anti-ASGP receptor antiserum. Protection of the mature forms was quantified by densitometric scanning, and normalized to the high-mannose precursor form. The complex and high-mannose glycosylated forms of H1 are indicated by C and H, respectively.

to the result obtained after similar treatment of the hepatoma cell line HepG2 which expresses the native ASGP receptor (lanes 1 and 2). H1(Δ 4-33A), however, was completely protected (lanes 7 and 8). During a 30-min incubation at 37°C with proteinase K, all complex H1 (97%) was digested (lanes 3 and 6), reflecting surface appearance of initially intracellular protein. In contrast, H1(Δ 4-33A) was 100% protected even at 37°C, indicating that the mutant protein did not pass through the plasma membrane to a significant extent within 30 min (lane 9).

H1(Δ 4-33A) Undergoes Trans-Golgi Modifications

The fact that H1(Δ 4-33A) was found in an endo H-resistant form (Fig. 4, lanes 1–5) indicated that the mutant protein exited the ER and reached at least the medial-Golgi. To test whether H1(Δ 4-33A) reached the *trans*-Golgi, we analyzed the incorporation of sialic acid and sulfation of tyrosine residues, two *trans*-Golgi-specific modifications (Roth et al., 1985; Baeuerle and Huttner, 1987). Upon neuraminidase digestion of M1 and M1 Δ cell lysates, the endo H-resistant forms of wild-type H1 and of H1(Δ 4-33A) were both slightly shifted on immunoblots, indicative of desialylation (Fig. 4, lanes 6–9). Subunit H1 is not naturally sulfated. However, we have recently shown that addi-

tion of a 9-residue tyrosine sulfation peptide to the extracellular carboxy terminus of the protein allows efficient labeling with [³⁵S]sulfate in a stable-transfected MDCK cell line (Leitinger et al., 1994). The tyrosine sulfation tag was introduced into the mutant H1(Δ 4-33A) and stable expressing MDCK cell lines, named M1 Δ ^{TS}, were generated. The tagged protein H1(Δ 4-33A)^{TS} accumulated intracellularly like H1(Δ 4-33A), as judged by immunofluorescence microscopy and proteinase K digestion (not shown). Upon labeling with [³⁵S]sulfate, radioactivity was incorporated into the endo H-resistant form of H1(Δ 4-33A)^{TS} with similar efficiency as into H1^{TS}, the tagged version of H1 (Fig. 4, lanes 10–12). These results indicate that H1(Δ 4-33A) reaches the *trans*-Golgi/TGN.

H1(Δ 4-33A) Accumulates in a Late Golgi Compartment

To determine whether H1(Δ 4-33A) is localized in the *trans*-Golgi, endosomes, or lysosomes, the immunofluorescence staining pattern of H1(Δ 4-33A) was compared to that of defined markers. As markers for endosomes and lysosomes we used fluorescein-conjugated dextran internalized for 5–15 min at 37°C, and the lysosomal membrane protein LAMP-1, respectively. As illustrated in Fig. 5 (A–C), the staining patterns of these markers differed considerably from the labeling of H1(Δ 4-33A). *Trans*-Golgi was visualized using antibodies directed against human galactosyltransferase transiently expressed in MDCK cells, yielding a staining pattern similar to that of H1(Δ 4-33A) (E). Furthermore, endogenous γ -adaptin (a TGN marker; D) and the cation-independent mannose-6-phosphate (M6P) receptor (present in the TGN, endosomes, and the plasma membrane; F) were predominantly immunolocalized to a similar juxtannuclear region as H1(Δ 4-33A).

To allow double-labeling experiments, H1(Δ 4-33A) was tagged at its carboxy terminus with an antigenic epitope of the *c-myc* oncogene product (mutant H1[Δ 4-33A]^{myc}). This modification did not alter the intracellular distribution. Double labeling of MDCK cells cotransfected with H1(Δ 4-33A)^{myc} and human galactosyltransferase cDNAs showed that the tubular structures characteristic for H1(Δ 4-33A) were almost indistinguishable from the structures labeled with anti-galactosyltransferase antibody (Fig. 6, A and B). In the stable cell line M1 Δ , the structures labeled with the H1-specific antibody also overlapped with the or-




Figure 4. Golgi-specific modification of H1 and H1(Δ 4-33A). M1 and M1 Δ cells were solubilized, digested without (-) or with endoglycosidase H (H; lanes 2–5) or neuraminidase (N; lanes 6–9), and analyzed by gel electrophoresis and immunoblot analysis. The stable MDCK cell lines M1^{TS} (lane 10) and M1 Δ ^{TS} (lanes 11 and 12; two clonal lines with different expression levels) expressing H1^{TS} or H1(Δ 4-33A)^{TS}, respectively, were labeled with [³⁵S]sulfate, solubilized, and subjected to immunoprecipitation using anti-ASGP receptor antiserum. The immunoprecipitates were analyzed by gel electrophoresis and fluorography.




Figure 5. Immunofluorescence localization of H1(Δ 4-33A) and different marker proteins. M1 Δ cells were processed for immunofluorescence microscopy using antibodies directed against H1(Δ 4-33A) (A), LAMP-1 (C; as a marker for lysosomes), γ -adaptin (D; as a marker for TGN), transfected human galactosyltransferase (E; as a marker for *trans*-Golgi), or cation-independent M6P receptor (F). To stain endosomes, M1 Δ cells were loaded for 10 min with FITC-dextran before fixation (B). Bar, 5 μ m.

ganelles stained by the anti- γ -adaptin antibody (Fig. 6, C and D). Similar overlap of signals was observed in BHK-21 cells (used because of the species specificity of the antibody) for endogenous TGN-38/41 and transfected H1(Δ 4-33A)^{myc} (not shown). These experiments strongly indicate that the mutant H1(Δ 4-33A) accumulates in the Golgi, and based on the modification by sialyltransferase and protein sulfotransferase most likely in the *trans*-Golgi and/or TGN.

This localization is supported by the effect of agents known to perturb specific organelles. Treatment of M1 Δ cells with okadaic acid or nocodazole, which are known to induce fragmentation of the Golgi apparatus (Lucocq et al., 1991; Ho et al., 1989b; Turner and Tartakoff, 1989), re-

sulted in redistribution of H1(Δ 4-33A) staining throughout the cytoplasm (not shown). The fungal metabolite brefeldin A was recently shown to cause the formation of tubules of the TGN in MDCK cells, while the medial-Golgi stacks were unaffected (Wagner et al., 1994). Under similar conditions, we observed the appearance of thin tubules containing H1(Δ 4-33A) as well as galactosyltransferase extending from the juxtannuclear region into the cytoplasm (not shown). In contrast, the distribution of H1(Δ 4-33A) was not affected by chloroquine, which causes lysosomal proteins to be depleted from lysosomes (Lippincott-Schwartz and Fambrough, 1987).

Proteins with mutations affecting folding and oligomerization are mostly retained in the ER by chaperones. Mu-




Figure 6. Double-immunofluorescence localization of H1(Δ 4-33A) and *trans*-Golgi marker proteins. (A and B) MDCK cells transiently transfected with H1(Δ 4-33A)^{myc} and human galactosyltransferase cDNAs were fixed, permeabilized, and stained with anti-myc (A) and anti-galactosyltransferase antibodies (B) followed by corresponding secondary antibodies coupled to fluorescein and rhodamine, respectively. (C and D) M1 Δ cells were double-labeled with antibodies to H1 (C) and γ -adaptin (D). Bound antibody was visualized using secondary antibodies coupled to rhodamine and fluorescein, respectively. Arrowheads point at some of the structures costained by different antibodies. Bar, 5 μ m.

tant H1(Δ 4-33A), however, passes these quality control mechanisms and accumulates in a later compartment of the secretory pathway. The kinetics of ER-to-Golgi transport of H1(Δ 4-33A), as judged from the conversion of the endo H-sensitive precursor to the endo H-resistant mature form of the protein in pulse-chase experiments, were similar to those of wild-type H1 with 50% conversion after \sim 3 h (Fig. 7 A). Cross-linking experiments using difluorodinitrobenzene (Shia and Lodish, 1989) in M1 and M1 Δ cells showed similar formation of homodimers and -trimers of wild-type and mutant H1 (not shown).

Because conversion to the complex glycosylated form is slow, the half-lives of the mature wild-type and mutant proteins were determined using their sulfatable variants H1^{TS} and H1(Δ 4-33A)^{TS} which can be specifically labeled in their final forms with [³⁵S]sulfate. The mature mutant protein has a half-life of \sim 5 h which is somewhat shorter than that of the wild-type H1^{TS} of \sim 7 h (Fig. 7 B). In addition, inhibition of protein synthesis for 3.5 h with 100 μ g/ml cycloheximide did not change the distribution of H1(Δ 4-33A). Together these results argue against rapid missorting of H1(Δ 4-33A) to lysosomes with transient ac-

cumulation in the Golgi, but rather suggest an efficient mechanism of retention of H1(Δ 4-33A) in the Golgi.

Trans-Golgi Localization Depends on the Size of the Cytoplasmic Domain

To define the determinants for *trans*-Golgi accumulation, we prepared a series of H1 cDNA constructs with alterations in the cytoplasmic domain, shown in Fig. 1. These constructs were transiently expressed in MDCK cells and analyzed by indirect immunofluorescence microscopy for accumulation in the typical juxtanuclear, tubular Golgi structures vs transport to the plasma membrane. The results are summarized in Fig. 1. The immunofluorescence patterns of the most relevant constructs are shown in Fig. 8 (A–C).

Two previously prepared mutants, H1(Δ 4-11) (lacking the signal for basolateral sorting from the TGN) and H1(Δ 12-33), were both transported to the cell surface in stable expressing MDCK cell lines (Geffen et al., 1993). This is in contrast to H1(Δ 4-33A) with the combined deletion. Mutation of tyrosine-5 of H1(Δ 12-33) to alanine in




Figure 7. Maturation and degradation kinetics of H1 and H1(Δ 4-33A). (A) M1 and M1 Δ cells were pulse labeled with [³⁵S]methionine for 30 min and chased for up to 7.5 h. H1 and H1(Δ 4-33A) were immunoprecipitated and analyzed by gel electrophoresis and fluorography. The scanned intensity of the complex form in percent of the total of complex and high-mannose precursor forms is shown. (B) M1^{TS} and M1 Δ ^{TS} cells were pulse labeled with [³⁵S]sulfate for 30 min and chased for up to 20 h. H1^{TS} and H1(Δ 4-33A)^{TS} were immunoprecipitated and analyzed by gel electrophoresis and fluorography. The scanned intensity of each sample is expressed in percent of that without chase.

the construct H1(Δ 12-33/5A) also resulted in transport to the cell surface, arguing against a role of the tyrosine signal in surface transport.

In a series of amino-terminal deletions, H1(Δ 2-19) and H1(Δ 2-24) were expressed on the cell surface, whereas H1(Δ 2-28), H1(Δ 2-33), and H1(Δ 2-37) accumulated intracellularly in the typical tubular structures. H1(Δ 2-24) and H1(Δ 2-28) differ only by the four consecutive prolines 25-28. Separate deletion of the proline-rich segment 25-30 in H1(Δ Pro), however, did not significantly affect the wild-type distribution. Furthermore, deletion of the juxtamembranous segment of residues 26-40 did not prevent surface transport. These results show that no single sequence element in the cytoplasmic domain can be made responsible either for retention in the Golgi or for surface transport.

There is, however, a correlation between the size of the cytoplasmic domain and the fate of the mutant proteins (see Fig. 1). Constructs with cytoplasmic domains of 17 or more residues were all transported to the plasma membrane; those with domains of 13 or fewer amino acids were retained in the Golgi. To test this correlation, the cytoplas-

mic sequence of H1(Δ 4-33A) was extended by insertion of an unrelated sequence of 10 residues, the human *c-myc* epitope, in place of the initial deletion. The cytoplasmic domain of the resulting mutant H1(Δ 4-33m) thus consists of 21 amino acids. Upon expression in transfected MDCK cells, the protein did not accumulate intracellularly but was detected on the cell surface (Fig. 8 D). In addition, the cytoplasmic domain of H1 was replaced with that of the transferrin receptor. The resulting fusion protein H1T, with a cytoplasmic tail of 65 residues, was efficiently transported to the plasma membrane (Fig. 8 E). However, upon truncation of this domain to only 11 residues, the fusion protein H1T Δ was completely retained in the typical Golgi structures (Fig. 8 F). These results confirm that the localization of H1 does not depend on the sequence of the cytoplasmic domain, but rather on its size.

The Exoplasmic Domain in Combination with a Tailless Anchor is Sufficient for Golgi Localization

The transmembrane and/or exoplasmic portions of truncated H1 thus appear to be responsible for Golgi retention, modulated by the cytoplasmic domain. To test whether the transmembrane segment is sufficient for Golgi retention, this domain with the wild-type or the truncated cytoplasmic portion of H1 was fused to the exoplasmic portion of human aminopeptidase N, a type II cell surface protein. Both fusion proteins (constructs AN2 and AN2 Δ , illustrated in Fig. 9) were expressed on the cell surface of transiently transfected MDCK cells and did not accumulate in the Golgi (Fig. 9, A and B). Conversely, we tested whether the exoplasmic domain of H1 is sufficient for Golgi localization if anchored in the membrane by an artificial transmembrane segment. In the construct H1 Δ Leu₁₉ (Fig. 9), the luminal domain of H1 was fused to a generic hydrophobic sequence of 19 leucine residues preceded by the positively charged sequence MGPR, to warrant efficient membrane insertion. For a control, this short cytoplasmic tail was extended by the cytoplasmic sequence of wild-type H1 in the construct H1Leu₁₉. Whereas H1Leu₁₉ was efficiently expressed on the cell surface of transfected MDCK cells, H1 Δ Leu₁₉ accumulated in Golgi structures like H1(Δ 4-33A) (Fig. 9, C and D). The particular sequence of the transmembrane segment of H1 is thus not necessary for Golgi localization, whereas the exoplasmic portion of H1 is sufficient for Golgi retention in combination with a membrane anchor that lacks a sizable cytoplasmic domain.

Association with Subunit H2 Partially Restores Surface Expression of H1(Δ 4-33A)

In the functional ASGP receptor, H1 is part of a heterooligomeric complex with subunit H2, which has a cytoplasmic domain of 58 amino acids. To test whether association with H2 influences the localization of H1(Δ 4-33A), a stable MDCK cell line expressing mutant H1 and wild-type H2 was created. Localization of H1(Δ 4-33A) and H2 was assayed separately by immunofluorescence using subunit-specific antisera. In nonpermeabilized cells, both subunits could be visualized on the surface (Fig. 10, A and C). Furthermore, functional receptors could be detected on the cell surface by specific binding of ¹²⁵I-iodinated asialoorosomucoid (not shown) which is indicative of correct




Figure 8. Intracellular localization of cytoplasmic domain mutants of H1 in transfected MDCK cells. MDCK cells were transiently transfected with the cDNAs of wild-type H1 (A), H1(Δ 2-24) (B), H1(Δ 2-28) (C), H1(Δ 4-33m) (D), H1T (E), and H1T Δ (F). After fixation and permeabilization, the cells were stained with anti-H1 antiserum and fluorescein-conjugated secondary antibodies. Bar, 5 μ m.

hetero-oligomer formation. Thus, association with H2 rescued H1(Δ 4-33A) transport to the cell surface. In permeabilized cells, however, both subunits were also detected in typical Golgi structures (Fig. 10, B and D), indicating that hetero-oligomers were partially retained in the Golgi.

Discussion

Most mutations in secretory or membrane proteins either do not prevent surface transport or, if they perturb folding or oligomerization, cause retention and degradation in the ER. Very few mutants have been described that escape ER retention and accumulate in a Golgi compartment on

the way to the cell surface. It is conspicuous that in most of these cases the mutation involves the membrane anchor of the protein or the immediate flanking sequences, which have been identified as the segments important for retention of natural Golgi resident proteins. Well characterized cases are growth hormone fused to the transmembrane and cytoplasmic domain of vesicular stomatitis virus G protein (Guan and Rose, 1984), or to an uncleaved transmembrane segment of a GPI-anchored membrane protein (Moran and Caras, 1992); the insertion of an arginine into the signal/anchor domain of influenza virus neuraminidase (Sivasubramanian and Nayak, 1987); two point mutations close to the transmembrane segment of fowl plague virus





Figure 9. Intracellular localization of H1 fusion proteins. MDCK cells were transiently transfected with the cDNAs of the fusion proteins AN2 (A), AN2 Δ (B), H1Leu₁₉ (C), and H1 Δ Leu₁₉ (D). The cells were fixed, permeabilized, and stained with anti-aminopeptidase N (A and B) or anti-H1 antibodies (C and D). The structure of the fusion proteins is illustrated schematically (APN, aminopeptidase N). The predominant intracellular localization of the constructs is indicated as in Fig. 1 (PM, plasma membrane; G, *trans*-Golgi structures). Bars, 5 μ m.

hemagglutinin (Naruse et al., 1986; Garten et al., 1992); replacement of the transmembrane domain of dipeptidyl peptidase IV by that of aminopeptidase N (Low et al., 1994).

Here we describe mutants of a cell surface receptor, the ASGP receptor subunit H1, that pass the quality control mechanisms of the ER, but are retained in a later compartment of the secretory pathway and do not reach the plasma membrane. The site of accumulation was identified as the *trans*-Golgi/TGN based on biochemical and morphological evidence for the mutant H1(Δ 4-33A). The retained

protein was modified by the *trans*-Golgi-specific enzymes sialyltransferase and (when tagged with an appropriate acceptor sequence) tyrosylprotein sulfotransferase. By indirect immunofluorescence microscopy, the mutant was found in juxtannuclear structures that are distinct from endosomes and lysosomes, and that are also stained with antibodies directed against galactosyltransferase and γ -adap-tin. Furthermore, the effects of nocodazole, okadaic acid, brefeldin A, and chloroquine on the distribution of H1(Δ 4-33A) in MDCK cells were consistent with a *trans*-Golgi localization.




Figure 10. Coexpression of H1(Δ 4-33A) and subunit H2. Cells of the stable MDCK cell line M2/1 Δ (expressing H2 and H1[Δ 4-33A]) were fixed without (A and C) or with permeabilization (B and D) and stained with antibodies specific for subunit H1 (A and B) or for subunit H2 (C and D). Bar, 10 μ m.

The nature of the alteration in H1 resulting in Golgi accumulation was analyzed by a series of mutations in the cytoplasmic domain. The results cannot be explained by the accidental generation of a retention motif or the deletion of a hypothetical export signal. However, the localization of H1 mutants correlates with the size of their cytoplasmic domains. Deletion of more than two-thirds of the 40 cytoplasmic residues caused Golgi retention. Extension of the truncated tail of H1(Δ 4-33A) by insertion of 10 unrelated residues of *c-myc* again resulted in surface transport. Similarly, the 65-residue cytoplasmic domain of the transferrin receptor fused to the transmembrane and exoplasmic portion of H1 allowed surface transport, whereas truncation of the fusion protein's tail to only 11 residues yielded efficient Golgi retention. In contrast, tailless transferrin receptors have been reported to be transported to the cell surface (Gironès et al., 1991; Kundu and Nayak, 1994). Cytoplasmic sequences have been shown by mutational analysis to be necessary for endocytosis, basolateral transport, and sorting to lysosomes (summarized by Sandoval and Bakke, 1994). Mutant proteins lacking cytoplasmic sequences may be missorted to inappropriate post-Golgi compartments, but are generally not blocked in exit from the Golgi. Golgi retention of truncated H1 therefore appears to be due to a specific interaction of the trans-

membrane and/or exoplasmic portions of H1 with Golgi resident components. This interaction is impeded by large cytoplasmic domains. Coexpression of H1(Δ 4-33A) with wild-type H2 resulted in the formation of functional ligand-binding hetero-oligomers detectable on the cell surface. However, since both subunits could also be detected by immunofluorescence microscopy in the typical Golgi pattern, association with H2 only weakened the interaction of H1(Δ 4-33A) with the *trans*-Golgi.

The membrane anchor of H1(Δ 4-33A) was found not to be sufficient to retain a reporter protein, the exoplasmic portion of aminopeptidase N, in the Golgi. In addition, the particular sequence of the transmembrane segment is also not necessary for Golgi localization, since it can be replaced by an artificial sequence of 19 consecutive leucines without affecting the fate of the protein. The exoplasmic domain is thus responsible for the interaction of truncated H1 mutants with Golgi components. It remains to be investigated what the potential interaction partners in the *trans*-Golgi might be.

Mutagenesis of Golgi resident membrane proteins (glycosyltransferases and coronavirus M protein) revealed an involvement of the transmembrane domain and/or the exoplasmic flanking sequence in retention (Nilsson et al., 1991; Munro, 1991; Aoki et al., 1992; Burke et al., 1992;

Colley et al., 1992; Russo et al., 1992; Tang et al., 1992; Teasdale et al., 1992; Wong et al., 1992; Dahdal and Colley, 1993; Machamer et al., 1993; Ponnambalam et al., 1994). Two models for Golgi retention mechanisms have been proposed. According to the "kin recognition" hypothesis (Nilsson et al., 1994) homodimeric proteins may form large hetero-oligomers with other residents of the same Golgi compartment by interaction via their transmembrane and/or stalk regions. The size of these kin oligomers would prevent their inclusion into transport vesicles. The retained mutants of H1 might participate in *trans*-Golgi hetero-oligomers by an interaction that is sterically hindered by larger cytoplasmic domains.

An alternative model proposed by Bretscher and Munro (1993) implicates the length of the transmembrane segment in relation to the differing lipid compositions in the compartments of the secretory pathway. Shorter transmembrane segments would be retained in the Golgi, whereas longer ones would be transported further. Hence, it is conceivable that the size of the cytoplasmic domain might have an effect on the positioning of the transmembrane segments of the H1 oligomer within the lipid bilayer and, as a result, on how the exoplasmic domain is exposed in the lumen.

It has to be pointed out that even the wild-type ASGP receptor is significantly concentrated in the Golgi apparatus. By quantitative immunoelectron microscopy, ~20% of the ASGP receptor has been detected in the *trans*-Golgi in rat hepatocytes and in HepG2 cells (Geuze et al., 1983, 1984; Zijderhand-Bleekemolen et al., 1987; Stoorvogel et al., 1989). Cycloheximide, which blocks protein synthesis without affecting intracellular transport, caused depletion of poly-immunoglobulin receptor and 5'-nucleotidase from the Golgi, but did not affect the Golgi pools of the ASGP and M6P receptors (Geuze et al., 1984; van den Bosch et al., 1986). Also by immunofluorescence microscopy, the ASGP receptor subunits in HepG2 and transfected MDCK cells can be detected in juxtannuclear Golgi-like structures, although without the obvious tubular appearance of the staining observed for H1(Δ 4-33A) (e.g., Fig. 2 B). This Golgi pool of wild-type ASGP receptor may reflect an intrinsic affinity of the protein to Golgi components that is moderated by the cytoplasmic tail, and that leads to efficient Golgi retention when the cytoplasmic domain is sufficiently truncated.

The situation of wild-type and truncated forms of H1 with respect to intracellular localization is reminiscent of that of β -1,4-galactosyltransferase (Shur, 1993). Two mRNAs are generated by alternative promoters which encode two forms of the enzyme (Lopez et al., 1991). A short form with 11 cytoplasmic residues is localized specifically in the *trans*-Golgi. A long form with 13 additional amino-terminal residues is less efficiently retained and also found on the cell surface, where it acts as a cell adhesion molecule. Modulation of Golgi retention by the cytoplasmic domain may thus be a general mechanism for fine tuning the intracellular distribution of membrane proteins. Whether in the case of galactosyltransferase this is a specific effect of the additional sequence (e.g., by interaction with the cytoskeleton) or whether, as in the case of H1, simply the additional size of the cytoplasmic domain is responsible for reduced retention remains to be tested.

We thank Katja Huggel for technical assistance, Drs. C. Fuhrer and K. Fiedler for generating the F1(Δ 4-33A) cell line and the AN2 construct, respectively, and Drs. G. Banting, E. Berger, B. Hoflack, L. Kühn, O. Norén, E. Rodriguez-Boulan, H. Sjöström, and G. von Heijne for cDNAs and/or antibodies. We are grateful to Dr. Gillian Griffiths for initial contributions and for critically reading the manuscript.

This work was supported by grant 31-34008.92 from the Swiss National Science Foundation and by the Incentive Award of the Helmut Horten Foundation.

Received for publication 2 February 1995 and in revised form 6 April 1995.

References

- Aoki, D., N. Lee, N. Yamaguchi, C. Dubois, and M. N. Fukuda. 1992. Golgi retention of a *trans*-Golgi membrane protein, galactosyl-transferase, requires cysteine and histidine residues within the membrane-anchoring domain. *Proc. Natl. Acad. Sci. USA.* 89:4319-4323.
- Baeuerle, P. A., and W. B. Huttner. 1987. Tyrosine sulfation is a *trans*-Golgi-specific protein modification. *J. Cell Biol.* 105:2655-2664.
- Beltzer, J. P., K. Fiedler, C. Fuhrer, I. Geffen, C. Handschin, H. P. Wessels, and M. Spiess. 1991. Charged residues are major determinants of the transmembrane orientation of a signal-anchor sequence. *J. Biol. Chem.* 266:973-978.
- Bretscher, M. S., and S. Munro. 1993. Cholesterol and the Golgi apparatus. *Science (Wash. DC).* 261:1280-1281.
- Burke, J., J. M. Pettitt, H. Schachter, M. Sarkar, and P. A. Gleeson. 1992. The transmembrane and flanking sequences of β -1,2-N-acetylglucosaminyltransferase I specify medial-Golgi localization. *J. Biol. Chem.* 267:24433-24440.
- Colley, K. J., E. U. Lee, and J. C. Paulson. 1992. The signal anchor and stem regions of the β -galactoside α -2,6-sialyltransferase may each act to localize the enzyme to the Golgi apparatus. *J. Biol. Chem.* 267:7784-7793.
- Cullen, B. R. 1987. Use of eukaryotic expression technology in the functional analysis of cloned genes. *Methods Enzymol.* 152:684-704.
- Dahdal, R. Y., and K. J. Colley. 1993. Specific sequences in the signal anchor of the β -galactoside α -2,6-sialyltransferase are not essential for Golgi localization. Membrane flanking sequences may specify Golgi retention. *J. Biol. Chem.* 268:26310-26319.
- Ellis, L., E. Clauser, D. O. Morgan, M. Ederly, R. A. Roth, and W. J. Rutter. 1986. Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose. *Cell.* 45:721-732.
- Evan, G. I., G. K. Lewis, G. Ramsay, and J. M. Bishop. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. *Mol. Cell Biol.* 5:3610-3616.
- Fuhrer, C., I. Geffen, and M. Spiess. 1991. Endocytosis of the ASGP receptor H1 is reduced by mutation of tyrosine-5 but still occurs via coated pits. *J. Cell Biol.* 114:423-432.
- Fuhrer, C., I. Geffen, K. Huggel, and M. Spiess. 1994. The two subunits of the asialoglycoprotein receptor contain different sorting information. *J. Biol. Chem.* 269:3277-3282.
- Garten, W., C. Will, K. Buckard, K. Kuroda, D. Ortmann, K. Munk, C. Scholtissek, H. Schnittler, D. Drenckhahn, and H. D. Klenk. 1992. Structure and assembly of hemagglutinin mutants of fowl plague virus with impaired surface transport. *J. Virol.* 66:1495-1505.
- Geffen, I., C. Fuhrer, B. Leitinger, M. Weiss, K. Huggel, G. Griffiths, and M. Spiess. 1993. Related signals for endocytosis and basolateral sorting of the asialoglycoprotein receptor. *J. Biol. Chem.* 268:20772-20777.
- Geffen, I., H. P. Wessels, J. Roth, M. A. Shia, and M. Spiess. 1989. Endocytosis and recycling of subunit H1 of the asialoglycoprotein receptor is independent of oligomerization with H2. *EMBO (Eur. Mol. Biol. Organ.) J.* 8:2855-2862.
- Geuze, H. J., J. W. Slot, G. J. A. M. Strous, H. F. Lodish, and A. L. Schwartz. 1983. Intracellular site of asialoglycoprotein receptor-ligand uncoupling. Double-label immunoelectronmicroscopy during receptor mediated endocytosis. *Cell.* 32:277-287.
- Geuze, H. J., J. W. Slot, G. J. Strous, J. P. Luzio, and A. L. Schwartz. 1984. A cycloheximide-resistant pool of receptors for asialoglycoproteins and mannose 6-phosphate residues in the Golgi complex of hepatocytes. *EMBO (Eur. Mol. Biol. Organ.) J.* 3:2677-2685.
- Gironès, N., E. Alvarez, A. Seth, I. M. Lin, D. A. Latour, and R. J. Davis. 1991. Mutational analysis of the cytoplasmic tail of the human transferrin receptor—identification of a sub-domain that is required for rapid endocytosis. *J. Biol. Chem.* 266:19006-19012.
- Guan, J. L., and J. K. Rose. 1984. Conversion of a secretory protein into a transmembrane protein results in its transport to the Golgi complex but not to the cell surface. *Cell.* 37:779-787.
- Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989a. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene (Amst.)* 77:51-59.
- Ho, W. C., V. J. Allan, G. van Meer, E. G. Berger, and T. E. Kreis. 1989b. Reclustering of scattered Golgi elements occurs along microtubules. *Eur. J. Cell Biol.* 48:250-263.

- Hurtley, S. M., and A. Helenius. 1989. Protein oligomerization in the endoplasmic reticulum. *Annu. Rev. Cell Biol.* 5:277-307.
- Kawai, S., and M. Nishizawa. 1984. New procedure for DNA transfection with polycation and dimethyl sulfoxide. *Mol. Cell. Biol.* 4:1172-1174.
- Ktistakis, N. T., M. G. Roth, and G. S. Bloom. 1991. PtK1 cells contain a non-diffusible, dominant factor that makes the Golgi apparatus resistant to brefeldin-A. *J. Cell Biol.* 113:1009-1023.
- Kundu, A., and D. P. Nayak. 1994. Analysis of the signals for polarized transport of influenza ViNs (A/Wsn/33) neuraminidase and human transferrin receptor, type II transmembrane proteins. *J. Virol.* 68:1812-1818.
- Leitinger, B., J. L. Brown, and M. Spiess. 1994. Tagging secretory and membrane proteins with a tyrosine sulfation site: tyrosine sulfation precedes galactosylation and sialylation in COS-7 cells. *J. Biol. Chem.* 269:8115-8121.
- Lippincott-Schwartz, J., and D. M. Fambrough. 1987. Cycling of the integral membrane glycoprotein, LEP-100, between plasma membrane and lysosomes: kinetic and morphological analysis. *Cell.* 49:669-677.
- Lopez, L. C., A. Youakim, S. Evans, and B. D. Shur. 1991. Evidence for a molecular distinction between cell surface and Golgi forms of β 1,4-galactosyltransferase. *J. Biol. Chem.* 266:15984-15991.
- Low, S. H., B. L. Tang, S. H. Wong, and W. Hong. 1994. Golgi retardation in Madin-Darby canine kidney and chinese hamster ovary cells of a transmembrane chimera of two surface proteins. *J. Biol. Chem.* 269:1985-1994.
- Lucocq, J., G. Warren, and J. Pryde. 1991. Okadaic acid induces Golgi apparatus fragmentation and arrest of intracellular transport. *J. Cell Sci.* 100:753-759.
- Machamer, C. E., M. G. Grim, A. Esquela, S. W. Chung, M. Rolls, K. Ryan, and A. M. Swift. 1993. Retention of a cis Golgi protein requires polar residues on one face of a predicted α -helix in the transmembrane domain. *Mol. Biol. Cell.* 4:695-704.
- Moran, P., and I. W. Caras. 1992. Proteins containing an uncleaved signal for glycosylphosphatidylinositol membrane anchor attachment are retained in a post-ER compartment. *J. Cell Biol.* 119:763-772.
- Munro, S. 1991. Sequences within and adjacent to the transmembrane segment of alpha-2,6-sialyltransferase specify Golgi retention. *EMBO (Eur. Mol. Biol. Organ.) J.* 10:3577-3588.
- Nabi, I. R., A. Lebivic, D. Fambrough, and E. Rodriguez-Boulant. 1991. An endogenous MDCK lysosomal membrane glycoprotein is targeted basolaterally before delivery to lysosomes. *J. Cell Biol.* 115:1573-1584.
- Naruse, H., C. Scholtissek, and H. D. Klenk. 1986. Temperature-sensitive mutants of fowl plague virus defective in the intracellular transport of hemagglutinin. *Virus Res.* 5:293-305.
- Nilsson, T., J. M. Lucocq, D. Mackay, and G. Warren. 1991. The membrane spanning domain of β -1,4-galactosyltransferase specifies trans-Golgi localization. *EMBO (Eur. Mol. Biol. Organ.) J.* 10:3567-3575.
- Nilsson, T., M. H. Hoe, P. Slusarewicz, C. Rabouille, R. Watson, F. Hunte, G. Watzel, E. G. Berger, and G. Warren. 1994. Kin recognition between medial Golgi enzymes in HeLa cells. *EMBO (Eur. Mol. Biol. Organ.) J.* 13:562-574.
- Pelham, H. R. B., and S. Munro. 1993. Sorting of membrane proteins in the secretory pathway. *Cell.* 75:603-605.
- Pfeffer, S. R., and J. E. Rothman. 1987. Biosynthetic protein transport and sorting by the endoplasmic reticulum and Golgi. *Annu. Rev. Biochem.* 56:829-852.
- Ponnambalam, S., C. Rabouille, J. P. Luzio, T. Nilsson, and G. Warren. 1994. The TGN38 glycoprotein contains two non-overlapping signals that mediate localization to the trans-Golgi network. *J. Cell Biol.* 125:253-268.
- Roth, J., D. J. Taatjes, J. M. Lucocq, J. Weinstein, and J. C. Paulson. 1985. Demonstration of an extensive trans-tubular network continuous with the Golgi apparatus stack that may function in glycosylation. *Cell.* 43:287-295.
- Russo, R. N., N. L. Shaper, D. J. Taatjes, and J. H. Shaper. 1992. β 1,4-galactosyltransferase—a short NH₂-terminal fragment that includes the cytoplasmic and transmembrane domain is sufficient for Golgi retention. *J. Biol. Chem.* 267:9241-9247.
- Sandoval, I. V., and O. Bakke. 1994. Targeting of membrane proteins to endosomes and lysosomes. *Trends Cell Biol.* 4:292-297.
- Shia, M. A., and H. F. Lodish. 1989. The two subunits of the human asialoglycoprotein receptor have different fates when expressed alone in fibroblasts. *Proc. Natl. Acad. Sci. USA.* 86:1158-1162.
- Shur, B. D. 1993. Glycosyltransferases as cell adhesion molecules. *Curr. Opin. Cell Biol.* 5:854-863.
- Sivasubramanian, N., and D. P. Nayak. 1987. Mutational analysis of the signal-anchor domain of influenza virus neuraminidase. *Proc. Natl. Acad. Sci. USA.* 84:1-5.
- Spiess, M. 1990. The asialoglycoprotein receptor—a model for endocytic transport receptors. *Biochemistry.* 29:10009-10018.
- Spiess, M., and C. Handschin. 1987. Deletion analysis of the internal signal-anchor domain of the human asialoglycoprotein receptor H1. *EMBO (Eur. Mol. Biol. Organ.) J.* 6:2683-2691.
- Spiess, M., A. L. Schwartz, and H. F. Lodish. 1985. Sequence of human asialoglycoprotein receptor cDNA. An internal signal sequence for membrane insertion. *J. Biol. Chem.* 260:1979-1982.
- Stoorvogel, W., H. J. Geuze, J. M. Griffith, A. L. Schwartz, and G. J. Strous. 1989. Relations between the intracellular pathways of the receptors for transferrin, asialoglycoprotein, and mannose 6-phosphate in human hepatoma cells. *J. Cell Biol.* 108:2137-2148.
- Tang, B. L., S. H. Wong, S. H. Low, and W. J. Hong. 1992. The transmembrane domain of N-glucosaminyltransferase-I contains a Golgi retention signal. *J. Biol. Chem.* 267:10122-10126.
- Teasdale, R. D., G. D'Agostaro, and P. A. Gleeson. 1992. The signal for Golgi retention of bovine β 1,4-galactosyltransferase is in the transmembrane domain. *J. Biol. Chem.* 267:4084-4096.
- Turner, J. R., and A. M. Tartakoff. 1989. The response of the Golgi complex to microtubule alterations: the roles of metabolic energy and membrane traffic in Golgi complex organization. *J. Cell Biol.* 109:2081-2088.
- van den Bosch, R. A., H. J. Geuze, and G. J. Strous. 1986. Presence of asialoglycoprotein receptors in the Golgi complex in the absence of protein synthesis. *Exp. Cell Res.* 162:231-242.
- Wagner, M., A. K. Rajasekaran, D. K. Hanzel, S. Mayor, and E. Rodriguez-Boulant. 1994. Brefeldin A causes structural and functional alterations of the trans-Golgi network of MDCK cells. *J. Cell Sci.* 107:933-943.
- Wessels, H. P., I. Geffen, and M. Spiess. 1989. A hepatocyte-specific basolateral membrane protein is targeted to the same domain when expressed in Madin-Darby canine kidney cells. *J. Biol. Chem.* 264:17-20.
- Wong, S. H., S. H. Low, and W. J. Hong. 1992. The 17-residue transmembrane domain of β -galactoside α 2,6-sialyltransferase is sufficient for Golgi retention. *J. Cell Biol.* 117:245-258.
- Zijderhand-Bleekemolen, J. E., A. L. Schwartz, J. W. Slot, G. J. Strous, and H. J. Geuze. 1987. Ligand- and weak base-induced redistribution of asialoglycoprotein receptors in hepatoma cells. *J. Cell Biol.* 104:1647-1654.